Lexaria Bioscience Corp. (CSE:LXX, OTCQX:LXRP)) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces recent animal testing proves that combining Lexaria’s DehydraTECHTM delivery technology with generic nanotech techniques delivers 1,137% more cannabidiol (“CBD”) into animal brain tissue following oral ingestion than certain existing industry formulations.

BACKGROUND


On March 20, 2019, Lexaria announced it was beginning a series of animal studies with multiple objectives that included developing a better understanding of how effectively edible forms of cannabinoids cross the blood-brain-barrier (“BBB”) to enter brain tissue. Results from these studies continue to generate additional data.

In this arm of animal study, Lexaria combined its DehydraTECH delivery technology with a standard form of nanotechnology and analyzed subsequent delivery into brain tissue following oral ingestion. Lexaria earlier proved in 2018 through two series of animal tests that its DehydraTECH delivers nicotine across the BBB more effectively than industry standards. This new research sought to confirm whether the same is true for cannabinoids. Lexaria also tested for differences in brain delivery rates between its patented long chain fatty acid (“LCFA”) CBD formulations without nanotech processing with those of medium chain triglycerides (“MCT”).

TEST RESULTS

In each arm of the Lexaria animal studies, 10 male Sprague-Dawley rats were orally administered CBD at the rate of 25mg per kg of bodyweight. Delivery of CBD into the brain was reported 8 hours after dosing.

In working with nanoemulsion processing equipment, Lexaria has developed a methodology to combine DehydraTECH with nanoemulsification for specific performance applications. Lexaria does not work with inorganic materials for purposes of nano-transformation since inorganic materials manipulated with nanotech have at times indicated poor health outcomes in animal testing. Lexaria’s patented formulations rely only on Generally Recognized As Safe (“GRAS”) organic ingredients.

  • – The Lexaria DehydraTECH LCFA formulation without nanotech achieved an average brain tissue accumulation level that was 246% higher than the average for those animals that received the MCT oil formulation (p=0.0013).

    – The Lexaria DehydraTECH LCFA formulation WITH nanotech achieved an average brain tissue accumulation level that was 1,137% higher than the average for those animals that received the MCT oil formulation (p=0.0178).

CONCLUSION

DehydraTECH has now been proven in several series of animal tests in 2018 and 2019 to greatly assist the delivery of drugs including nicotine and cannabinoids across the BBB. Demonstration of the effectiveness of DehydraTECH together with nanoemulsification greatly expands the applicability of the technology both for conventional edible dosage forms and for consumable liquid and beverage dosage forms that are gaining ever increasing popularity.

Lexaria will make available to its licensed corporate clients throughout North America the benefits of Lexaria’s recent technological advances through existing and new technology license agreements as rapidly as it is possible to customize each unique client formulation.

The full universe of classes of drugs that might be more efficiently delivered across the BBB using DehydraTECH has not yet been quantified but, in part owing to the fact that certain profound advantages might be exploited within the pharmaceutical industry, Lexaria does expect to conduct additional work during 2019 to try to determine what some of those drug classes may be. Lexaria will utilize its wholly-owned Lexaria Pharmaceutical subsidiary to pursue opportunities outside of cannabinoids and nicotine related to more effective BBB transport of other drug classes.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

 For regular updates, connect with Lexaria on Twitter https://twitter.com/lexariacorp

 and on Facebook https://www.facebook.com/lexariabioscience/

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.

Alex Blanchard, Communications Manager

(250)765-6424 Ext 202

Or

NetworkNewsWire (NNW)

www.NetworkNewsWire.com

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. Scientific R&D is often unpredictable and unanticipated results could emerge from any study and have a material impact.There is no assurance that any planned corporate activity, scientific study, R&D, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). TurboCBDTM, DehydraTECHTM technology and ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Click here to connect with Lexaria Bioscience Corp. (CSE:LXX, OTCQX:LXRP) for an Investor Presentation. 

Source: www.thenewswire.com

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less

Combined entity creates a market leader in the extract and extract derivatives market.

Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), announces that further to its press release issued on December 23, 2020, it has completed the acquisition of all of the issued and outstanding securities of Premium 5 Ltd. (“Premium 5”), a Canada-based recreational and medical cannabis company and market leader in high-quality full spectrum concentrates.

Keep reading... Show less

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) is pleased to announce it has engaged Pure Product Brokers for sales representation for Better Plant’s Urban Juve products, commencing immediately.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/72806_b5ea59a054310a89_001.jpg

Keep reading... Show less

Online ordering and doorstep delivery have become the new normal as patients and consumers continue to rely on convenient and sustainable delivery services

World-Class Extractions Inc. (CSE:PUMP) (FRA:WCF) (OTCQB:WCEXF) (“Company” or “World-Class”), is pleased to provide an update on Pineapple Express Delivery Inc. (“Pineapple Express Delivery” or “PED”), a company in which World-Class has a controlling interest. PED is a leading logistics technology company offering compliant and secure delivery of controlled substances and regulated products, including medical and recreational cannabis delivery in Ontario, Manitoba and Saskatchewan, and liquor delivery in certain jurisdictions in Saskatchewan

Pineapple Express Delivery – Highlights

The following PED revenues comprise of delivery services of medical and recreational cannabis within Ontario and Manitoba to various Business-to-Consumer and Business-to-Business licensed producer companies and liquor deliveries in Saskatchewan:

  • December 2020 revenues totaled $889,935 (November – $837,875) with gross margin of 34% (November – 30%) (unaudited).
  • November 2020 revenues totaled $837,875 (October – $795,580) with gross margin of 30% (October – 30%) (unaudited).
  • As a result of recent COVID-19 prevention measures, B2C revenue increased approximately 7% in November over October 2020 and an additional 4% in December over November 2020, mainly from an increase in the recreational delivery segment.
  • During 2020:
    • monthly revenue grew from $131,179 in January 2020 to $889,935 in December 2020, representing an increase of 578%; and
    • number of deliveries grew from 11,077 in January 2020 compared to 70,802 in December 2020, representing an increase of 539%.

The Company cautions that figures for revenue, gross profit and net income generated from the services offered by Pineapple Express Delivery have not been audited beyond April 30, 2020 and are based on calculations prepared by the management of Pineapple Express Delivery. Actual results may differ from those reported in this release once figures have been audited.

Pineapple Express Delivery – Operational Achievements

Since the Company’s acquisition of a controlling interest in PED, PED has achieved the following operational milestones:

  • In addition to continuing to offer premium delivery services for recreational and medical cannabis products, PED expanded its delivery services to provide same-day and next-day delivery of wine, spirits and beer products from Saskatoon Co-op’s Wine-Spirits-Beer retail stores in Saskatoon, Warman and Martensville.
  • The number of cannabis and alcohol deliveries continues to increase month over month with 67,279 deliveries rendered in November, and 70,802 in December, compared to 62,327 deliveries in October.
  • The number of drivers increased from 55 at the beginning of 2020, to approximately 200 by December 2020. Efficiencies have also been created by routing deliveries through hub expansions and concentrating drivers to tighter geographical areas, leading to less hours used by drivers for the timely delivery of packages.
  • Within the province of Ontario, PED offers same day cannabis delivery service in 37 cities (183 postal code regions) and 3-day service in 65 cities (288 postal code regions).
  • Expanded its services into the Ontario cities of Ottawa, Barrie, London and also into the Windsor/Chatham region.
  • Launched and commenced operations of PED cannabis depots (hubs) in Ottawa, Kingston, London and in the Windsor/Chatham region.
  • Partnered with Medical Cannabis by Shoppers™ to offer same-day delivery to their medical cannabis patients in cities in and around the Greater Toronto Area (GTA). Medical Cannabis by Shoppers™ is Shoppers Drug Mart’s online platform for the sale of medical cannabis.
  • Partnered with Spectrum Therapeutics, the medical division of Canopy Growth Corporation to bring same-day delivery to medical cannabis patients in the GTA, from Hamilton to Scarborough. This builds on PED’s existing services contract with Canopy Growth which offers same-day delivery services for Tweed and Tokyo Smoke retail stores in Manitoba and Saskatchewan.
  • Subsequent to the period ending October, 31, 2020, PED entered into a licensing agreement to provide software and support services to an arm length party. PED shall provide set-up, implementation and development of the software and shall provide support to all locations catered to by the other party.
  • Several contracts in place with Health Canada License Holders for delivery within select provinces in Canada.
  • Late-stage applicant to Health Canada to obtain a ‘Sale for Medical Purposes’ license for its facility located in the GTA. With a population of 6-million people, this sales license gives PED the ability to store inventory for other license holders, allowing PED to leverage its facility in the GTA and offer same day delivery services to the patients of those LPs.

Pineapple Express Delivery – Expansion Strategies

Pineapple Express Delivery continues to advance into new territories, offering safe and secure delivery opportunities to better serve the public. PED anticipates its revenues will increase over the coming months resulting from jurisdictional expansion and continuously improving and expanding its delivery services offerings:

  • Working to launch in three (3) new jurisdictions in Ontario.
  • Working to launch alcohol delivery to service the GTA.
  • Continuing growth of deliveries for the B2B sector which has seen month-over-month increases in revenue since May 2020.
  • Expects to launch prescription medication delivery in British Columbia and the GTA in the near term.

Pineapple Express Delivery – Growth in Delivery Services: COVID-19 and Beyond

Aspiring to be the ‘Amazon’ of regulated product deliveries, Pineapple Express Delivery is based in Burlington, Ontario, providing B2C and B2B delivery options for controlled substances and regulated products deliveries (cannabis, alcohol and prescription products). PED is currently one of the premiere, most utilized delivery services in Ontario, and will continue to maintain its high standards of security and compliance for same day and next day parcels, even as it grows to meet provincial need.

PED benefits from a management team with over 10 years of experience offering same-day delivery services in multiple industries across Canada. Its founder, Randy Rolph, founded Menu Express delivery in Quebec in 2010, which was subsequently purchased by Just Eat in 2014. Mr. Rolph then founded Delivery Direct in 2015, becoming the national leader in 60 min delivery. The proprietary logistics software behind Just Eat and Delivery Direct brings the most reliable same-day, last mile delivery services for the controlled substances and regulated market across Canada.

The COVID-19 pandemic has forever changed shopping behaviours. With the unfortunate outbreak of COVID-19 and the cannabis sector deemed an ‘essential’ service, there has been a surge in demand for delivery with more and more people staying indoors and practicing social distancing. Cannabis patients and consumers have embraced delivery to safely access regulated products, and PED is experiencing increased demand for its services. In response to this surge in volume, PED has increased the number of delivery drivers to over 200 in 2020.

An increase in deliveries during a health crisis also equates to an increase in routine and preventative measures. As such, PED has implemented strict COVID-19 practices and procedures in its offices, warehouses, and in delivery driver procedures, including equipping all driver vehicles with a 360º security camera. PED ensures that its staff has the necessary tools to abide by Health Canada and provincial health guidelines, including face coverings, gloves, hand sanitizer, and disinfectants.

Rosy Mondin, CEO of World Class Extractions stated, “The COVID-19 pandemic has created an urgent demand for home delivery like we’ve never seen before and it’s unlikely that Canadians will ever return to their old shopping habits. People shop online because of convenience – and online shopping and delivery of legal cannabis is no different. E-commerce is thriving, and according to a recent Paypal study, online shopping increased by 53% as more people self-isolated and worked from home, and over 45% of consumers also used home delivery[1]”. Ms. Mondin continued, “Given the history of cannabis legalization, there still exists a lingering stigma of physically visiting retail cannabis stores for many new consumers. After months of lockdown and social distancing pushing more patients and consumers online, Canadians have come to value the convenience of a legal, proven and reliable delivery solution for cannabis and other regulated products, a trend that is likely to stay.”

Randy Rolph, Founder & CEO of Pineapple Express Delivery stated, “In 2020, we have seen the public health and economic crises of the COVID-19 pandemic take a terrible toll on many Canadians and Canadian businesses and we are proud to be a platform that so many Canadians have been able to use to during these difficult times. The guiding principles of PED is that patients and consumers should be able to receive their regulated product orders (alcohol, prescription medications and cannabis) as quickly, safely and as easily as they can obtain any other product in Canada. The pandemic is far from over and many of the habits formed during this pandemic will likely stick post-pandemic. PED’s widespread network and large delivery fleet provides important, much-needed access to thousands of patients and consumers every day.”

About World-Class

World-Class is an innovation-driven company with a principle focus on the rapidly evolving cannabis and hemp industries. World-Class offers compliant and secure delivery of government regulated products through its subsidiary Pineapple Express Delivery Inc., including medical and recreational cannabis in Ontario, Manitoba and Saskatchewan, and liquor delivery in certain jurisdictions in Saskatchewan. World-Class continues to investigate opportunities to deploy and manage custom-built extraction centres utilizing its custom systems, technology, and processes to efficiently produce high-quality cannabis and hemp concentrates and end-products.

Investor Contact
World-Class Investor Relations
1-437-266-1968
ir@worldclassextractions.com
https://worldclassextractions.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, and the ability of Pineapple Express Delivery to expand its delivery services and to provide discrete shipment of products. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less